About Us
Innovative Drugs
News
Join Us
Contact Us
Keyword:
Latest News
Jiangsu Vcare PharmaTech’s Balanced, Highly Selective New-Generation JAK1 Inhibitor VC005 Tablets Completes First Participant Enrollment in Phase II Clinical Trial for Alopecia Areata
Vcare PharmaTech Completes Full Participant Enrollment in Phase III Clinical Trial of VC005 Tablets, a New‑Generation Balanced High‑Selectivity JAK1 Inhibitor, for Ankylosing Spondylitis
Vcare PharmaTech’s VC005 Tablets, a New‑Generation Balanced Highly‑Selective JAK1 Inhibitor, Achieves Positive Top‑line Results in Phase II Clinical Trial for Vitiligo
PanTRKare™ Officially Approved as the Companion Diagnostic for VELMARTO® (Eratrectinib)
China's First Independently Developed NTRK Inhibitor Eratrectinib (VELMARTO®) Receives Approval to Initiate Pivotal Clinical Trial in Pretreated Drug-Resistant Patients
IF=17.5! Phase I Data of Eratrectinib Published in Experimental Hematology & Oncology